SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

IgG1 Fc N-glycan galactosylation as a biomarker for immune activation.

de Jong, SE; Selman, MHJ; Adegnika, AA; Amoah, AS; van Riet, E; Kruize, YCM; Raynes, JG; Rodriguez, A; Boakye, D; von Mutius, E; et al. de Jong, SE; Selman, MHJ; Adegnika, AA; Amoah, AS; van Riet, E; Kruize, YCM; Raynes, JG; Rodriguez, A; Boakye, D; von Mutius, E; Knulst, AC; Genuneit, J; Cooper, PJ; Hokke, CH; Wuhrer, M; Yazdanbakhsh, M (2016) IgG1 Fc N-glycan galactosylation as a biomarker for immune activation. Scientific Reports, 6. p. 28207. ISSN 2045-2322 https://doi.org/10.1038/srep28207
SGUL Authors: Cooper, Philip John

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

Immunoglobulin G (IgG) Fc N-glycosylation affects antibody-mediated effector functions and varies with inflammation rooted in both communicable and non-communicable diseases. Worldwide, communicable and non-communicable diseases tend to segregate geographically. Therefore, we studied whether IgG Fc N-glycosylation varies in populations with different environmental exposures in different parts of the world. IgG Fc N-glycosylation was analysed in serum/plasma of 700 school-age children from different communities of Gabon, Ghana, Ecuador, the Netherlands and Germany. IgG1 galactosylation levels were generally higher in more affluent countries and in more urban communities. High IgG1 galactosylation levels correlated with low total IgE levels, low C-reactive protein levels and low prevalence of parasitic infections. Linear mixed modelling showed that only positivity for parasitic infections was a significant predictor of reduced IgG1 galactosylation levels. That IgG1 galactosylation is a predictor of immune activation is supported by the observation that asthmatic children seemed to have reduced IgG1 galactosylation levels as well. This indicates that IgG1 galactosylation levels could be used as a biomarker for immune activation of populations, providing a valuable tool for studies examining the epidemiological transition from communicable to non-communicable diseases.

Item Type: Article
Additional Information: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Scientific Reports
ISSN: 2045-2322
Language: ENG
Dates:
DateEvent
16 June 2016Published
28 April 2016Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
INCO-CT-2006-032405Sixth Framework Programmehttp://dx.doi.org/10.13039/501100004965
HEALTH-2009-242107Seventh Framework Programmehttp://dx.doi.org/10.13039/501100004963
HEALTH-2011-278535Seventh Framework Programmehttp://dx.doi.org/10.13039/501100004963
DFG- Projekt KR 1150/6-1Deutsche Forschungsgemeinschafthttp://dx.doi.org/10.13039/501100001659
PubMed ID: 27306703
Web of Science ID: WOS:000378107700001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/108024
Publisher's version: https://doi.org/10.1038/srep28207

Actions (login required)

Edit Item Edit Item